Aslan Pharma raises US$34m in fresh funding

Singapore

THE Republic's fledgling pharma ecosystem on Monday got a shot in the arm as biotech startup Aslan Pharmaceuticals announced it has raised US$34 million in Series C funding led by Accuron Technologies, a tech subsidiary of Temasek Holdings.

The proceeds, said Aslan, will be used to further accelerate clinical development of its pipeline of four novel therapeutic agents, all of which have the potential to treat tumour types "prevalent in Asia", such as gastric, bile duct and breast cancers.